Stay updated on Study CB-839 + Paclitaxel in TNBC: Clinical Trial
Sign up to get notified when there's something new on the Study CB-839 + Paclitaxel in TNBC: Clinical Trial page.

Latest updates to the Study CB-839 + Paclitaxel in TNBC: Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov page’s footer revision marker changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe record presents details of a completed Phase 2 trial combining CB-839 with paclitaxel for advanced triple-negative breast cancer, including its participant cohorts, eligibility criteria, and study outcomes. It also includes study locations, record dates, and supporting documents.SummaryDifference71%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden page.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Study CB-839 + Paclitaxel in TNBC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Study CB-839 + Paclitaxel in TNBC: Clinical Trial page.